Admedus Ltd started its life as Allied Healthcare Group Ltd when its two parent companies Allied Medical Ltd and bioMD Ltd (ASX: BOD) merged in 2011. In 2013, the Company changed its name from Allied Healthcare Group to Admedus Ltd as part of a global branding strategy, and acquired Verigen Australia Pty Ltd (now Admedus Biomanufacturing).
The original merger of Allied Healthcare Group Ltd and bioMD Ltd created a unique healthcare company with assets in research & development, products in advanced clinical trials ready for commercialisation, and a successful sales, marketing and medical device distribution business.
BioMD listed on the ASX in 2004 and had successfully developed the assets of regenerative tissue engineering company Celxcel.
Allied Medical Ltd was originally spun out of Fortescue Metals Group Limited (FMG) and became an independent entity in November 2005.
Allied’s growth strategy was founded upon leveraging its core competencies in sales, distribution and commercialisation to support its investments in growth areas – sectors identified as having the potential to make a significant and positive contribution in the healthcare sector.
In 2008, Allied identified a partnership to gain entry in the growing vaccine market with a right to acquire a majority shareholding in Coridon Pty Ltd (Coridon), a company founded by Professor Ian Frazer, Australian of the Year 2006. Professor Frazer is well recognised for his ground breaking research that led to Merck & Co.’s highly successful cervical cancer vaccine, Gardasil®.
The Coridon partnership fitted well with Allied’s long term strategic goal of creating shareholder value through identifying opportunities and investing in innovative technologies that have global potential with world class research expertise. Since then the Company has worked closely with Ian Frazer and his team to develop a vaccines portfolio looking at areas such as herpes simplex virus 2 (HSV-2) and human papillomavirus (HPV). Today this section of the business is known as Admedus Immunotherapies.
In 2010, Allied expanded its sales and distribution business with the acquisition of Medevco Pty Ltd. Medevco was an Australian-based supplier and distributor of medical devices and had an existing sales, marketing, logistics and technical service footprint across Australia and New Zealand.
Admedus Ltd came into being in November 2013 as part of a global branding strategy and name change for ASX listed Allied Healthcare Group Ltd. The entry of the company into key markets in Europe and the plan to enter the US market early in 2014 required a clearly defined company name that has the ability to differentiate from other existing businesses. Allied Healthcare Group Ltd which was established in June 2011, through the merger of Allied Medical Ltd an unlisted public company and bioMD Ltd an ASX listed company (ASX: BOD).
As a result of its rich history and strategic acquisitions, Admedus Ltd is a global company with a de-risked profile in tissue engineering, immunotherapies, biomanufacturing and sales.